Navigation Links
Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc.
Date:6/3/2008

ALEXANDRIA. Va., June 3 /PRNewswire/ -- Oxford Finance Corporation and ATEL Ventures, Inc., today announced they have provided a $7.5 million senior secured loan to AxoGen, a privately held, venture-backed life science company.

AxoGen is a leader in the advancement of peripheral nerve repair. Their patented product, AVANCE(TM) Nerve Graft is a biological solution used by surgeons for the repair and regeneration of peripheral nerves.

"Oxford's and ATEL's support will allow us to continue our focused efforts on the AVANCE(TM) Nerve Graft, as well as support a rich pipeline of new products furthering AxoGen's commitment to improve the standard of care for patients with peripheral nerve injuries," said Jamie Grooms, AxoGen chief executive officer and co-founder.

"Oxford is pleased to provide capital to support AxoGen's continuing growth," said J. Alden Philbrick, president and chief executive officer of Oxford Finance Corporation. "Their technology is quite unique and a promising solution for people with peripheral nerve damage."

About Oxford Finance Corporation

Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, is a specialty finance firm providing senior secured loans to public and private life science companies worldwide. For 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1 billion in loans, with lines of credit ranging from $500 thousand to $30 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California and Massachusetts. For more information, visit http://www.oxfordfinance.com.

About ATEL Ventures, Inc.

Since its founding in 1977, San Francisco-based ATEL Capital Group has become the largest private and closely-held independent leasing company in the United States, with approximately $2 billion in asset-secured transactions under management. ATEL Capital formed ATEL Ventures, Inc. to provide working capital and equipment financing term loans to emerging growth companies in information technology, life sciences, specialty retail and alternative energy. For information about ATEL Ventures, contact Steven Rea, executive vice president, or visit their website at http://www.atel.com/ventures.

About AxoGen, Inc.

Based in Alachua, Florida, AxoGen is committed to supporting surgeons in their efforts to improve the standard of care for patients with peripheral nerve injuries by "Bringing the Science of Nerve repair to Life." The company is privately held and has received funding from Accuitive Medical Ventures, Cardinal Partners, De Novo Ventures, Springboard Capital II, LLC, SynoGen, and Emergent Growth Fund.


'/>"/>
SOURCE Oxford Finance Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
2. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
3. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
4. Oxford Finance Corporation and GE Healthcare Financial Services Reaffirm Commitment to Biotech Sector in Europe
5. Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors
6. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
7. Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board
8. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
9. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
10. Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
11. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Village, CA (PRWEB) , ... August 17, 2017 ... ... technology for cancer research and personalized medicine, today announced the launch of a ... Kansas City, Missouri. The study’s goal is to evaluate the potential for early ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... different cell type. Many treatments for specific cancers, such as breast, prostate, or ... treatment is androgen deprivation therapy for advanced prostate cancer. , This therapy ...
(Date:8/16/2017)... ... August 16, 2017 , ... We are proud to announce ... at our Dilworth, MN site. The inspection took place Monday, July 31st through ... part of a routine Bioresearch Monitoring Program (BIMO) with the USFDA wherein multiple ...
(Date:8/15/2017)... STANFORD, Calif. , Aug. 15, 2017 After spending ... resources and support with crowdsourced data collection, GeneFo now offers this ... interested in aligning and amplifying support, adherence, and data collection vis ... with medical foundations mark the successful launch of this offer. ... GeneFo ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
Breaking Biology News(10 mins):